An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors. (Q53251841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Keren Levanon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

S Carvalho

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

M Lindzen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

N Shirazi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

S Sinha

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Abdul-Hai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

J Korach

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

I Barshack

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Y Cohen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A Onn

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

G Mills

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Y Yarden

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

27 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

438-447

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2015.93

6 March 2020

exact match

0 references

cites work

Roles for growth factors in cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

EGFR family: structure physiology signalling and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

ErbB receptors and signaling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

A module of negative feedback regulators defines growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Quantitative modeling perspectives on the ErbB system of cell regulatory processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Engineering epidermal growth factor for enhanced mitogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Amphiregulin exosomes increase cancer cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Structure and function of human amphiregulin: a member of the epidermal growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Affinity regulates spatial range of EGF receptor autocrine ligand binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Differential effects of EGFR ligands on endocytic sorting of the receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Systems biology of growth factor-induced receptor endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Dual-specificity MAP kinase phosphatases (MKPs) and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

New developments in the treatment of ovarian cancer--future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

The ERBB network: at last, cancer therapy meets systems biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

The EGF domain: requirements for binding to receptors of the ErbB family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Autocrine secretion and malignant transformation of cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

The ErbB receptors and their ligands in cancer: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

The biology of ovarian cancer: new opportunities for translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Binding specificities and affinities of egf domains for ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.93

31 March 2020

Identifiers

DOI

10.1038/ONC.2015.93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25915843%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference